{"id":"NCT02095158","sponsor":"Allergan","briefTitle":"A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea","officialTitle":"A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-08","completion":"2015-09","firstPosted":"2014-03-24","resultsPosted":"2016-09-21","lastUpdate":"2019-11-18"},"enrollment":440,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Erythema","Rosacea"],"interventions":[{"type":"DRUG","name":"Oxymetazoline HCL Cream 1.0%","otherNames":["AGN-199201"]}],"arms":[{"label":"Oxymetazoline HCL Cream 1.0%","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Related Adverse Events","timeFrame":"56 Weeks","effectByArm":[{"arm":"Oxymetazoline HCL Cream 1.0%","deltaMin":8.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":440},"commonTop":[]}}